AtheroNova has signed an agreement with Frontage Laboratories to begin work on the formulation, compounding and tableting of AHRO-001 for Phase I studies. Frontage will immediately commence work on the analysis, formulation and validation of the various processes and procedures for manufacturing AHRO-001 tablets for AtheroNova.

“Frontage has been extremely diligent in dealing with the technical and physical requirements of our AHRO-001 compound and we look forward to commencing our project in the coming days,” said AtheroNova chief executive officer, Thomas W. Gardner. “We are very confident that Frontage will deliver a quality product in a timely manner. We continue to adhere to our vigorous development path and anticipate additional exciting development milestones in the coming months.”

“We are pleased to be working with the fine people from Frontage on this project as we continue to engage with quality industry partners,” said Dr. Balbir Brar, senior vice president of Drug Development at AtheroNova. “Our utmost confidence stems from previous projects I have worked on with Frontage and have always found their people, facilities and product quality to be some of the best in the industry.”